Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Immunol. Jul 27, 2014; 4(2): 98-106
Published online Jul 27, 2014. doi: 10.5411/wji.v4.i2.98
Published online Jul 27, 2014. doi: 10.5411/wji.v4.i2.98
GM3-containing nanoparticles in immunosuppressed hosts: Effect on myeloid-derived suppressor cells
Audry Fernández, Liliana Oliver, Rydell Alvarez, Circe Mesa, Immunobiology Division, Center of Molecular Immunology, Havana 11600, Cuba
Luis E Fernández, Innovation Division, Center of Molecular Immunology, Havana 11600, Cuba
Author contributions: Fernández A, Oliver L, Alvarez R, Fernández LE and Mesa C drafted the review and wrote the paper.
Supported by Center of Molecular Immunology
Correspondence to: Circe Mesa, PhD, Director of Immunobiology Division, Center of Molecular Immunology, 216 St. and 15th Avenue, Atabey, Playa, PO Box 16040, Havana 11600, Cuba. circe@cim.sld.cu
Telephone: +53-7-2143161 Fax: +53-7-2720644
Received: March 8, 2014
Revised: June 12, 2014
Accepted: June 27, 2014
Published online: July 27, 2014
Processing time: 141 Days and 17.6 Hours
Revised: June 12, 2014
Accepted: June 27, 2014
Published online: July 27, 2014
Processing time: 141 Days and 17.6 Hours
Core Tip
Core tip: Very small size proteoliposomes (VSSP) is a nanoparticulated adjuvant being used in the formulation of several cancer vaccines that are currently in clinical trials. In this review we summarize the unique ability of VSSP to stimulate antigen-specific CD8+ T cell responses in tumor-bearing mice and in mice with chemotherapy-induced leukopenia, both immunosuppressive scenarios frequently found in cancer patients. As a possible mechanism of this efficacy, we have focused on the modulation of myeloid-derived suppressor cells (MDSCs) by these nanoparticles, in the context of the current knowledge about the interaction of cancer vaccine adjuvants with MDSCs.